[Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].

OBJECTIVE: To evaluate the safety and efficacy of Firebird drug-eluting stent (DES) combining Tirofiban and Cypher DES combining Tirofiban in patients with acute coronary syndrome (ACS). METHODS: 323 ACS patients were divided into 2 general conditions-matched groups: Firebird group (n = 161) undergoing Firebird DES implantation and Tirofiban intravenous injection 10 microg x kg(-1) within 3 minutes followed by Tirofiban 0.15 microg x kg(-1) x min(-1) intravenous maintenance infusion with micro pump for 36 hours, and Cypher group (n = 162) undergoing Cypher DES implantation and Tirofiban. The safety was observed instantly and 36 h after the implantation. The patients were followed up for 30 d. Some patients in the Firebird group underwent coronary angiography and intravascular ultrasound because of angina and part of target vessels underwent revascularization. RESULTS: There were no significant differences between the 2 groups in ejection fraction target coronary lesion type, blood platelet count, HB and HCT before treatment. The success rates of operation were both 100% in these 2 groups. No complication occurred in both groups. There were not significant differences in the blood platelet count, hemoglobin, hematocrit, acute stent thrombosis rate (1.2% vs 1.2%), acute myocardial infarction rate (1.3% vs 1.3%), target vessel revascularization rate (0.6% vs 1.3%), and rehospitalization rate (1.3% vs 0.7%) (all P > 0.05). 30 d no in-stent restenosis was found by angiographic and intravascular ultrasound follow-up in the Firebird group. CONCLUSION: Firebird DES combining Tirofiban and Cypher DES combining Tirofiban are both safe and effective in treating ACS.